{"id":24542,"date":"2022-01-12T14:13:41","date_gmt":"2022-01-12T11:13:41","guid":{"rendered":"https:\/\/zdmaa.com\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/"},"modified":"2022-01-13T13:00:52","modified_gmt":"2022-01-13T10:00:52","slug":"recent-cancer-drug-approval-turning-point-for-lung-cancer","status":"publish","type":"post","link":"https:\/\/zdmaa.com\/tr\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/","title":{"rendered":"Yeni kanser ilac\u0131 onay\u0131: akci\u011fer kanseri i\u00e7in bir devrilme noktas\u0131"},"content":{"rendered":"

Yeni kanser ilac\u0131 onay\u0131: akci\u011fer kanseri i\u00e7in bir devrilme noktas\u0131<\/span><\/span><\/span><\/span><\/p>\n

\n

L<\/span><\/span><\/span> Ung’un kanseri uzun zamand\u0131r Amerika’daki en \u00f6l\u00fcmc\u00fcl kanser olarak k\u00f6t\u00fc \u015f\u00f6hrete sahip. <\/span>Bu hastal\u0131k her y\u0131l yakla\u015f\u0131k 160.000 Amerikal\u0131 erkek ve kad\u0131n\u0131 \u00f6ld\u00fcr\u00fcr ve d\u00f6rt kanserden birine neden olur ve kolon kanseri, meme kanseri ve prostat kanserinin toplam\u0131ndan fazlas\u0131n\u0131 \u00f6ld\u00fcr\u00fcr. <\/span>Ancak bir\u00e7ok uzman, iki nedenden dolay\u0131 akci\u011fer kanserine kar\u015f\u0131 sava\u015fta bir d\u00f6n\u00fcm noktas\u0131 g\u00f6rd\u00fcklerine inan\u0131yor: \u0130lerlemi\u015f vakalar\u0131 tedavi etmek i\u00e7in daha fazla yeni ila\u00e7 onaylan\u0131yor ve onkologlar art\u0131k sava\u015ft\u0131klar\u0131 hastal\u0131k hakk\u0131nda her zamankinden daha fazla \u015fey biliyorlar. <\/span>Phoenix CTCA\u00ae <\/span><\/span>Akci\u011fer<\/span><\/span><\/sup> Kanseri Merkezi t\u0131bbi direkt\u00f6r\u00fc ve Phoenix Hastanesi onkologu Ashish Sangal, \u201cAkci\u011fer kanseri tedavisinin gelece\u011fi \u00e7ok parlak g\u00f6r\u00fcn\u00fcyor\u201d dedi. <\/span>Bu iyimserlik, b\u00fcy\u00fck \u00f6l\u00e7\u00fcde, tedavi paradigmalar\u0131ndaki, herkese uyan tek bir yakla\u015f\u0131mdan daha bireyselle\u015ftirilmi\u015f bak\u0131ma ge\u00e7i\u015ften kaynaklanmaktad\u0131r.<\/span><\/span><\/p>\n

Onkologlar akci\u011fer kanserini iki kategoriye ay\u0131r\u0131r: 10 akci\u011fer kanserinden dokuzunu olu\u015fturan k\u00fc\u00e7\u00fck h\u00fccreli olmayan ve akci\u011fer kanserlerinin y\u00fczde 20’sinden az\u0131n\u0131 olu\u015fturan k\u00fc\u00e7\u00fck h\u00fccreli. <\/span>On y\u0131l \u00f6nce, tedavi kararlar\u0131 \u00e7ok az ek bilgi gerektiriyordu. <\/span>Her tip ayn\u0131 tekniklerle tedavi edildi, genellikle erken evrelerinde akci\u011fer kanserleri i\u00e7in ameliyat ve ileri evrelerde olanlar i\u00e7in kemoterapi. <\/span>G\u00fcn\u00fcm\u00fczde akci\u011fer kanseri tedavileri hastal\u0131\u011f\u0131n birden fazla t\u00fcr\u00fc ve evresi taraf\u0131ndan belirlenmektedir. <\/span>\u00d6rne\u011fin kanser k\u00fc\u00e7\u00fck h\u00fccreli olmayan akci\u011fer kanseriyse, onkologlar bunun skuam\u00f6z h\u00fccreli mi yoksa k\u00fc\u00e7\u00fck h\u00fccreli olmayan akci\u011fer kanserinin iki ana alt tipi olan adenokarsinom mu oldu\u011funa karar verir. <\/span>Ayr\u0131ca, t\u00fcm\u00f6r\u00fcn davran\u0131\u015f\u0131n\u0131 y\u00f6nlendirebilecek mutasyonlar\u0131 aramak i\u00e7in baz\u0131 hastalarda genomik testler yaparlar. <\/span>CTCA Akci\u011fer Kanseri Enstit\u00fcs\u00fc’nde t\u0131bbi onkoloji direkt\u00f6r\u00fc ve Atlanta Hastanesi’nde t\u0131bbi bir onkolog olan Patricia Rich, \u015funlar\u0131 s\u00f6yl\u00fcyor:<\/span><\/span><\/p>\n

Erken evre k\u00fc\u00e7\u00fck h\u00fccreli olmayan akci\u011fer kanseri tedavileri y\u0131llar i\u00e7inde olduk\u00e7a de\u011fi\u015fti; <\/span>Birinci basamak tedavi, yayg\u0131n alternatifler aras\u0131nda radyoterapi ve kemoterapi ile cerrahi olmaya devam etmektedir. <\/span>Ancak son zamanlarda onkologlar ve ila\u00e7 geli\u015ftiriciler, kanseri v\u00fccudun di\u011fer b\u00f6lgelerine yay\u0131lm\u0131\u015f hastalar i\u00e7in tedavi se\u00e7eneklerini geni\u015fletmeye ba\u015flad\u0131lar. <\/span>Bu \u00e7abalar\u0131n b\u00fcy\u00fck \u00e7o\u011funlu\u011fu, akci\u011fer kanserinin y\u00fczde 85’ini olu\u015fturan k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanserine y\u00f6neliktir.<\/span><\/span><\/p>\n

Yeni ila\u00e7 onaylar\u0131<\/span><\/span><\/h2>\n

Son y\u0131llarda, ABD G\u0131da ve \u0130la\u00e7 Dairesi (FDA), k\u00fc\u00e7\u00fck h\u00fccreli olmayan akci\u011fer kanseri h\u00fccrelerinin b\u00fcy\u00fcmesine yard\u0131mc\u0131 olan spesifik genetik de\u011fi\u015fiklikleri hedef alan yeni ila\u00e7lar\u0131 onaylad\u0131. <\/span>Bu hedefe y\u00f6nelik tedavilerden baz\u0131lar\u0131, kanser h\u00fccrelerinin yeni kan damarlar\u0131 olu\u015fturmas\u0131n\u0131 \u00f6nlemeye \u00e7al\u0131\u015f\u0131r; <\/span>Di\u011ferleri, kanser h\u00fccrelerinin b\u00fcy\u00fcmesini ve b\u00f6l\u00fcnmesini \u00f6nlemek i\u00e7in EGFR, ALK ve BRAF gibi belirli protein resept\u00f6rlerindeki DNA mutasyonlar\u0131n\u0131 n\u00f6tralize etmek \u00fczere tasarlanm\u0131\u015ft\u0131r. <\/span>Dr. Sangal, “Bu hedefe y\u00f6nelik ila\u00e7lar\u0131n ne yaz\u0131k ki yard\u0131mc\u0131 olabilece\u011fi \u00e7ok k\u00fc\u00e7\u00fck bir insan alt k\u00fcmesidir” diyor. <\/span>“K\u00fc\u00e7\u00fck h\u00fccreli olmayan akci\u011fer kanseri hastalar\u0131n\u0131n yaln\u0131zca y\u00fczde 15’inde EGFR mutasyonu var ve \u00f6rne\u011fin yaln\u0131zca y\u00fczde 5’inde ALK mutasyonu var. Ancak bu ila\u00e7larla bu hastalardan o kadar iyi yan\u0131t al\u0131yorsunuz ki ihtiyac\u0131n\u0131z yok” bunu d\u00fc\u015f\u00fcnmek i\u00e7in.”<\/span><\/span><\/p>\n

Onkologlar ayr\u0131ca, bir hastan\u0131n kanseri de\u011fi\u015ftik\u00e7e ve ilerledik\u00e7e hedefe y\u00f6nelik tedavilerin nas\u0131l kullan\u0131laca\u011f\u0131 hakk\u0131nda \u00f6\u011frenecekleri daha \u00e7ok \u015fey oldu\u011funu biliyorlar. <\/span>Dr. Sangal, “Hedefe y\u00f6nelik tedavi i\u015fe yarasa ve bir ki\u015finin kanseri bir veya iki y\u0131l i\u00e7inde kaybolsa bile, kanser ikinci hatta \u00fc\u00e7\u00fcnc\u00fc bir mutasyon oldu\u011fu i\u00e7in geri gelebilir” diyor.<\/span><\/span><\/p>\n

“Neredeyse zarif bir yumruk gibi. Kanser yeni mutasyonlar olu\u015fturuyor ve bu yeni mutasyonlar\u0131 \u00f6nlemek i\u00e7in yeni ila\u00e7lar bulmam\u0131z gerekiyor.” <\/span><\/span>– Ashish Sangal, Dr.<\/span><\/span><\/em><\/p><\/blockquote>\n

G\u0131da ve \u0130la\u00e7 \u0130daresi, k\u00fc\u00e7\u00fck h\u00fccreli olmayan akci\u011fer kanserini tedavi etmek i\u00e7in kontrol noktas\u0131 inhibit\u00f6rleri olarak adland\u0131r\u0131lan birka\u00e7 imm\u00fcnoterapi ilac\u0131n\u0131 da yak\u0131n zamanda onaylad\u0131: pembrolizumab (Keytruda <\/span><\/span>\u00ae<\/span><\/span><\/sup> ), nivolumab (Opdivo <\/span><\/span>\u00ae<\/span><\/span><\/sup> ) ve atezolizumab (Tecentriq <\/span><\/span>\u00ae<\/span><\/span><\/sup> ). <\/span>Bu ila\u00e7lar, ba\u011f\u0131\u015f\u0131kl\u0131k tepkisini d\u00fczenlemeye yard\u0131mc\u0131 olan PD-1 ve PD-L1 h\u00fccre resept\u00f6rlerini hedefler. <\/span>Tedaviler, yaln\u0131zca kemoterapiye veya di\u011fer tedavilere yan\u0131t vermeyen belirli k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri t\u00fcrlerine sahip hastalar i\u00e7in onaylanm\u0131\u015ft\u0131r. <\/span>Pembrolizumab ayr\u0131ca baz\u0131 hastalarda kemoterapi ile kombinasyon halinde veya tek ba\u015f\u0131na birinci basamak tedavi olarak onaylanm\u0131\u015ft\u0131r.<\/span><\/span><\/p>\n

Kanser tedavisine ek olarak, imm\u00fcnoterapiler baz\u0131 hastalar i\u00e7in daha iyi bir ya\u015fam kalitesi anlam\u0131na da gelebilir, \u00e7\u00fcnk\u00fc yorgunluk ve mide bulant\u0131s\u0131 gibi yan etkileri kemoterapi ve di\u011fer geleneksel tedavilerle ili\u015fkili olanlardan genellikle daha az ciddidir. <\/span>Ancak az say\u0131da hasta i\u00e7in imm\u00fcnoterapi ciddi, ya\u015fam\u0131 tehdit eden reaksiyonlara neden olabilir. <\/span>Daniel Nader, DO, FCCP, FACP, Amerika Kanser Tedavi Merkezleri\u00ae (CTCA) akci\u011fer hizmetleri <\/span><\/span>\u015fefi<\/span><\/span><\/sup> . <\/span>Bu gibi durumlarda, karaci\u011fer veya kolon iltihaplanabilir ve tedavinin ertelenmesi veya tamamen durdurulmas\u0131 gerekebilir.<\/span><\/span><\/p>\n

Kombinasyon terapilerini ke\u015ffedin<\/span><\/span><\/h2>\n

Bununla birlikte, ilac\u0131n s\u0131n\u0131rlamalar\u0131na ra\u011fmen, onkologlar akci\u011fer kanseri hastalar\u0131 i\u00e7in imm\u00fcnoterapinin gelece\u011fi konusunda iyimserler. <\/span>Dr. Rich, “Kontrol noktas\u0131 \u00f6nleyici ila\u00e7larla ilgili daha fazla denemenin geldi\u011fini ve hastalar i\u00e7in daha iyi bir se\u00e7im oldu\u011funu g\u00f6r\u00fcyorum” diyor. <\/span>“Kontrol noktalar\u0131 ve hastalar\u0131 tedavi etmek i\u00e7in onlarla nas\u0131l \u00e7al\u0131\u015f\u0131laca\u011f\u0131 hakk\u0131nda daha fazla \u015fey \u00f6\u011frendik\u00e7e, daha fazla mutasyonu tedavi edebilen daha fazla ila\u00e7 g\u00f6rece\u011fiz.” <\/span>\u00d6rne\u011fin, Eyl\u00fcl ay\u0131nda <\/span><\/span>New England Journal of Medicine’de bir \u00e7al\u0131\u015fma yay\u0131nland\u0131.<\/span><\/span><\/em>Kemoterapi ve radyoterapi ve ard\u0131ndan kontrol noktas\u0131 inhibit\u00f6r\u00fc ila\u00e7 durvalumab (IMFINZI\u2122) ile tedavi edilen evre III k\u00fc\u00e7\u00fck h\u00fccreli olmayan akci\u011fer kanserli hastalar\u0131n, sadece kemoterapi ve radyoterapi ile tedavi edilenlerden daha uzun ya\u015fad\u0131\u011f\u0131 bulundu. <\/span>diyor. <\/span>Rich: “Talebin onaylanaca\u011f\u0131n\u0131 d\u00fc\u015f\u00fcn\u00fcyorum.” <\/span>“Ve belki de budur: yay\u0131lm\u0131\u015f ve cerrahi olarak \u00e7\u0131kar\u0131lamayan k\u00fc\u00e7\u00fck h\u00fccreli olmayan akci\u011fer kanserleri i\u00e7in s\u0131ral\u0131 imm\u00fcnoterapi.”<\/span><\/span><\/p>\n

Dr. Sangal, umut verici sonu\u00e7lar g\u00f6steren di\u011fer form\u00fclasyonlar\u0131n ufukta oldu\u011funu s\u00f6yl\u00fcyor. <\/span>“Tedaviler, bir hastan\u0131n sahip oldu\u011fu kanser t\u00fcr\u00fcne g\u00f6re \u00e7ok bireysel hale geliyor” diyor. <\/span>“Bu sadece tedaviyi \u00e7antadan \u00e7\u0131karmakla ilgili de\u011fil. \u00c7ok \u00e7e\u015fitli fakt\u00f6rlerde hastan\u0131n nereye ait oldu\u011funu belirlemekle ilgili.”<\/span><\/span><\/p>\n

Hem diyette hem de kansere kar\u015f\u0131 m\u00fccadelede ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin nas\u0131l \u00e7al\u0131\u015ft\u0131\u011f\u0131 hakk\u0131nda daha fazla bilgi edinin.<\/span><\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Yeni kanser ilac\u0131 onay\u0131: akci\u011fer kanseri i\u00e7in bir devrilme noktas\u0131 L Ung’un kanseri uzun zamand\u0131r Amerika’daki en \u00f6l\u00fcmc\u00fcl kanser olarak k\u00f6t\u00fc \u015f\u00f6hrete sahip. Bu hastal\u0131k her y\u0131l yakla\u015f\u0131k 160.000 Amerikal\u0131 erkek ve kad\u0131n\u0131 \u00f6ld\u00fcr\u00fcr ve d\u00f6rt kanserden birine neden olur ve kolon kanseri, meme kanseri ve prostat kanserinin toplam\u0131ndan fazlas\u0131n\u0131 \u00f6ld\u00fcr\u00fcr. Ancak bir\u00e7ok uzman, iki …<\/p>\n","protected":false},"author":1,"featured_media":23223,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[],"class_list":["post-24542","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized-tr"],"yoast_head":"\nYeni kanser ilac\u0131 onay\u0131: akci\u011fer kanseri i\u00e7in bir devrilme noktas\u0131 - zdmaa<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/zdmaa.com\/tr\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yeni kanser ilac\u0131 onay\u0131: akci\u011fer kanseri i\u00e7in bir devrilme noktas\u0131 - zdmaa\" \/>\n<meta property=\"og:description\" content=\"Yeni kanser ilac\u0131 onay\u0131: akci\u011fer kanseri i\u00e7in bir devrilme noktas\u0131 L Ung’un kanseri uzun zamand\u0131r Amerika’daki en \u00f6l\u00fcmc\u00fcl kanser olarak k\u00f6t\u00fc \u015f\u00f6hrete sahip. Bu hastal\u0131k her y\u0131l yakla\u015f\u0131k 160.000 Amerikal\u0131 erkek ve kad\u0131n\u0131 \u00f6ld\u00fcr\u00fcr ve d\u00f6rt kanserden birine neden olur ve kolon kanseri, meme kanseri ve prostat kanserinin toplam\u0131ndan fazlas\u0131n\u0131 \u00f6ld\u00fcr\u00fcr. Ancak bir\u00e7ok uzman, iki …\" \/>\n<meta property=\"og:url\" content=\"https:\/\/zdmaa.com\/tr\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"zdmaa\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-12T11:13:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-01-13T10:00:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/doctor-g732783b80_640.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"427\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tahmini okuma s\u00fcresi\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 dakika\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/zdmaa.com\/tr\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/\",\"url\":\"https:\/\/zdmaa.com\/tr\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/\",\"name\":\"Yeni kanser ilac\u0131 onay\u0131: akci\u011fer kanseri i\u00e7in bir devrilme noktas\u0131 - zdmaa\",\"isPartOf\":{\"@id\":\"https:\/\/zdmaa.com\/tr\/ro\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/zdmaa.com\/tr\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/zdmaa.com\/tr\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/doctor-g732783b80_640.jpg\",\"datePublished\":\"2022-01-12T11:13:41+00:00\",\"dateModified\":\"2022-01-13T10:00:52+00:00\",\"author\":{\"@id\":\"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/8aad4cf5d562d4ca835487f6149853e3\"},\"breadcrumb\":{\"@id\":\"https:\/\/zdmaa.com\/tr\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/zdmaa.com\/tr\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/zdmaa.com\/tr\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/#primaryimage\",\"url\":\"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/doctor-g732783b80_640.jpg\",\"contentUrl\":\"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/doctor-g732783b80_640.jpg\",\"width\":640,\"height\":427,\"caption\":\"Recent Cancer Drug Approval: Turning Point for Lung Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/zdmaa.com\/tr\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629\",\"item\":\"https:\/\/zdmaa.com\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yeni kanser ilac\u0131 onay\u0131: akci\u011fer kanseri i\u00e7in bir devrilme noktas\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/zdmaa.com\/tr\/ro\/#website\",\"url\":\"https:\/\/zdmaa.com\/tr\/ro\/\",\"name\":\"zdmaa\",\"description\":\"zdmaa\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/zdmaa.com\/tr\/ro\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/8aad4cf5d562d4ca835487f6149853e3\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/zdmaa.com\/wp-content\/litespeed\/avatar\/dff6d89ac221c1aaf9366bf5b4cd32de.jpg?ver=1777164375\",\"contentUrl\":\"https:\/\/zdmaa.com\/wp-content\/litespeed\/avatar\/dff6d89ac221c1aaf9366bf5b4cd32de.jpg?ver=1777164375\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/zdmaa.com\"],\"url\":\"https:\/\/zdmaa.com\/tr\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Yeni kanser ilac\u0131 onay\u0131: akci\u011fer kanseri i\u00e7in bir devrilme noktas\u0131 - zdmaa","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/zdmaa.com\/tr\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/","og_locale":"tr_TR","og_type":"article","og_title":"Yeni kanser ilac\u0131 onay\u0131: akci\u011fer kanseri i\u00e7in bir devrilme noktas\u0131 - zdmaa","og_description":"Yeni kanser ilac\u0131 onay\u0131: akci\u011fer kanseri i\u00e7in bir devrilme noktas\u0131 L Ung’un kanseri uzun zamand\u0131r Amerika’daki en \u00f6l\u00fcmc\u00fcl kanser olarak k\u00f6t\u00fc \u015f\u00f6hrete sahip. Bu hastal\u0131k her y\u0131l yakla\u015f\u0131k 160.000 Amerikal\u0131 erkek ve kad\u0131n\u0131 \u00f6ld\u00fcr\u00fcr ve d\u00f6rt kanserden birine neden olur ve kolon kanseri, meme kanseri ve prostat kanserinin toplam\u0131ndan fazlas\u0131n\u0131 \u00f6ld\u00fcr\u00fcr. Ancak bir\u00e7ok uzman, iki …","og_url":"https:\/\/zdmaa.com\/tr\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/","og_site_name":"zdmaa","article_published_time":"2022-01-12T11:13:41+00:00","article_modified_time":"2022-01-13T10:00:52+00:00","og_image":[{"width":640,"height":427,"url":"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/doctor-g732783b80_640.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"admin","Tahmini okuma s\u00fcresi":"6 dakika"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/zdmaa.com\/tr\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/","url":"https:\/\/zdmaa.com\/tr\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/","name":"Yeni kanser ilac\u0131 onay\u0131: akci\u011fer kanseri i\u00e7in bir devrilme noktas\u0131 - zdmaa","isPartOf":{"@id":"https:\/\/zdmaa.com\/tr\/ro\/#website"},"primaryImageOfPage":{"@id":"https:\/\/zdmaa.com\/tr\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/#primaryimage"},"image":{"@id":"https:\/\/zdmaa.com\/tr\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/doctor-g732783b80_640.jpg","datePublished":"2022-01-12T11:13:41+00:00","dateModified":"2022-01-13T10:00:52+00:00","author":{"@id":"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/8aad4cf5d562d4ca835487f6149853e3"},"breadcrumb":{"@id":"https:\/\/zdmaa.com\/tr\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/zdmaa.com\/tr\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/zdmaa.com\/tr\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/#primaryimage","url":"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/doctor-g732783b80_640.jpg","contentUrl":"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/doctor-g732783b80_640.jpg","width":640,"height":427,"caption":"Recent Cancer Drug Approval: Turning Point for Lung Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/zdmaa.com\/tr\/recent-cancer-drug-approval-turning-point-for-lung-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629","item":"https:\/\/zdmaa.com\/tr\/"},{"@type":"ListItem","position":2,"name":"Yeni kanser ilac\u0131 onay\u0131: akci\u011fer kanseri i\u00e7in bir devrilme noktas\u0131"}]},{"@type":"WebSite","@id":"https:\/\/zdmaa.com\/tr\/ro\/#website","url":"https:\/\/zdmaa.com\/tr\/ro\/","name":"zdmaa","description":"zdmaa","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/zdmaa.com\/tr\/ro\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/8aad4cf5d562d4ca835487f6149853e3","name":"admin","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/image\/","url":"https:\/\/zdmaa.com\/wp-content\/litespeed\/avatar\/dff6d89ac221c1aaf9366bf5b4cd32de.jpg?ver=1777164375","contentUrl":"https:\/\/zdmaa.com\/wp-content\/litespeed\/avatar\/dff6d89ac221c1aaf9366bf5b4cd32de.jpg?ver=1777164375","caption":"admin"},"sameAs":["https:\/\/zdmaa.com"],"url":"https:\/\/zdmaa.com\/tr\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/posts\/24542","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/comments?post=24542"}],"version-history":[{"count":1,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/posts\/24542\/revisions"}],"predecessor-version":[{"id":24582,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/posts\/24542\/revisions\/24582"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/media\/23223"}],"wp:attachment":[{"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/media?parent=24542"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/categories?post=24542"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/tags?post=24542"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}